1. Executive Summary
1.1. Global Life Science Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Life Science Market Outlook, 2018 - 2031
3.1. Global Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Recombinant Proteins
3.1.1.1.1. Immune Checkpoint Regulators
3.1.1.1.2. Chemokines
3.1.1.1.3. Growth Factors
3.1.1.1.4. Cytokines
3.1.1.1.5. Colony Stimulating Factors
3.1.1.1.6. Hormones
3.1.1.1.7. Enzymes and Inhibitors
3.1.1.1.8. Others
3.1.1.2. Cell Lines
3.1.1.2.1. Immunotherapy Cell Lines
3.1.1.2.2. Ion Channel Cell Lines
3.1.1.2.3. GPCR Cell Lines
3.1.1.2.4. Cell Signaling Pathway Cell Lines
3.1.1.2.5. Gene Knockout Cell Lines
3.1.1.2.6. Cancer Cell Lines
3.1.1.2.7. Others
3.1.1.3. Antibodies
3.1.1.3.1. Immune Checkpoint Antibodies
3.1.1.3.2. Epitope Tag Antibodies
3.1.1.3.3. Isotype Control Antibodies
3.1.1.3.4. Primary Antibodies
3.1.1.3.5. Assay Antibodies
3.1.1.3.6. Others
3.1.1.4. Viable Tumor Samples
3.1.1.5. Tumor Tissue Microarrays
3.2. Global Life Science Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Drug Discovery and Development
3.2.1.2. Basic Research
3.2.1.3. Toxicity Screening
3.2.1.4. Biopharmaceutical Production
3.2.1.5. Drug Screening
3.2.1.6. Tissue Engineering
3.2.1.7. Forensic Testing
3.3. Global Life Science Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Biopharmaceutical Companies
3.3.1.2. Contract Research Organizations (CROs)
3.3.1.3. Academic & Research Institutes
3.3.1.4. Forensic Science Laboratories
3.3.1.5. Food & Beverage Companies
3.3.1.6. Diagnostic Centers
3.3.1.7. Others
3.4. Global Life Science Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Life Science Market Outlook, 2018 - 2031
4.1. North America Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Recombinant Proteins
4.1.1.1.1. Immune Checkpoint Regulators
4.1.1.1.2. Chemokines
4.1.1.1.3. Growth Factors
4.1.1.1.4. Cytokines
4.1.1.1.5. Colony Stimulating Factors
4.1.1.1.6. Hormones
4.1.1.1.7. Enzymes and Inhibitors
4.1.1.1.8. Others
4.1.1.2. Cell Lines
4.1.1.2.1. Immunotherapy Cell Lines
4.1.1.2.2. Ion Channel Cell Lines
4.1.1.2.3. GPCR Cell Lines
4.1.1.2.4. Cell Signaling Pathway Cell Lines
4.1.1.2.5. Gene Knockout Cell Lines
4.1.1.2.6. Cancer Cell Lines
4.1.1.2.7. Others
4.1.1.3. Antibodies
4.1.1.3.1. Immune Checkpoint Antibodies
4.1.1.3.2. Epitope Tag Antibodies
4.1.1.3.3. Isotype Control Antibodies
4.1.1.3.4. Primary Antibodies
4.1.1.3.5. Assay Antibodies
4.1.1.3.6. Others
4.1.1.4. Viable Tumor Samples
4.1.1.5. Tumor Tissue Microarrays
4.2. North America Life Science Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Drug Discovery and Development
4.2.1.2. Basic Research
4.2.1.3. Toxicity Screening
4.2.1.4. Biopharmaceutical Production
4.2.1.5. Drug Screening
4.2.1.6. Tissue Engineering
4.2.1.7. Forensic Testing
4.3. North America Life Science Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Biopharmaceutical Companies
4.3.1.2. Contract Research Organizations (CROs)
4.3.1.3. Academic & Research Institutes
4.3.1.4. Forensic Science Laboratories
4.3.1.5. Food & Beverage Companies
4.3.1.6. Diagnostic Centers
4.3.1.7. Others
4.4. North America Life Science Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Life Science Market by Application, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Life Science Market End User, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Life Science Market by Application, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Life Science Market End User, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Life Science Market Outlook, 2018 - 2031
5.1. Europe Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Recombinant Proteins
5.1.1.1.1. Immune Checkpoint Regulators
5.1.1.1.2. Chemokines
5.1.1.1.3. Growth Factors
5.1.1.1.4. Cytokines
5.1.1.1.5. Colony Stimulating Factors
5.1.1.1.6. Hormones
5.1.1.1.7. Enzymes and Inhibitors
5.1.1.1.8. Others
5.1.1.2. Cell Lines
5.1.1.2.1. Immunotherapy Cell Lines
5.1.1.2.2. Ion Channel Cell Lines
5.1.1.2.3. GPCR Cell Lines
5.1.1.2.4. Cell Signaling Pathway Cell Lines
5.1.1.2.5. Gene Knockout Cell Lines
5.1.1.2.6. Cancer Cell Lines
5.1.1.2.7. Others
5.1.1.3. Antibodies
5.1.1.3.1. Immune Checkpoint Antibodies
5.1.1.3.2. Epitope Tag Antibodies
5.1.1.3.3. Isotype Control Antibodies
5.1.1.3.4. Primary Antibodies
5.1.1.3.5. Assay Antibodies
5.1.1.3.6. Others
5.1.1.4. Viable Tumor Samples
5.1.1.5. Tumor Tissue Microarrays
5.2. Europe Life Science Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Drug Discovery and Development
5.2.1.2. Basic Research
5.2.1.3. Toxicity Screening
5.2.1.4. Biopharmaceutical Production
5.2.1.5. Drug Screening
5.2.1.6. Tissue Engineering
5.2.1.7. Forensic Testing
5.3. Europe Life Science Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Biopharmaceutical Companies
5.3.1.2. Contract Research Organizations (CROs)
5.3.1.3. Academic & Research Institutes
5.3.1.4. Forensic Science Laboratories
5.3.1.5. Food & Beverage Companies
5.3.1.6. Diagnostic Centers
5.3.1.7. Others
5.4. Europe Life Science Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Life Science Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Life Science Market End User, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Life Science Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Life Science Market End User, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Life Science Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Life Science Market End User, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Life Science Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Life Science Market End User, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Life Science Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Life Science Market End User, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Life Science Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Life Science Market End User, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Life Science Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Life Science Market End User, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Life Science Market Outlook, 2018 - 2031
6.1. Asia Pacific Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Recombinant Proteins
6.1.1.1.1. Immune Checkpoint Regulators
6.1.1.1.2. Chemokines
6.1.1.1.3. Growth Factors
6.1.1.1.4. Cytokines
6.1.1.1.5. Colony Stimulating Factors
6.1.1.1.6. Hormones
6.1.1.1.7. Enzymes and Inhibitors
6.1.1.1.8. Others
6.1.1.2. Cell Lines
6.1.1.2.1. Immunotherapy Cell Lines
6.1.1.2.2. Ion Channel Cell Lines
6.1.1.2.3. GPCR Cell Lines
6.1.1.2.4. Cell Signaling Pathway Cell Lines
6.1.1.2.5. Gene Knockout Cell Lines
6.1.1.2.6. Cancer Cell Lines
6.1.1.2.7. Others
6.1.1.3. Antibodies
6.1.1.3.1. Immune Checkpoint Antibodies
6.1.1.3.2. Epitope Tag Antibodies
6.1.1.3.3. Isotype Control Antibodies
6.1.1.3.4. Primary Antibodies
6.1.1.3.5. Assay Antibodies
6.1.1.3.6. Others
6.1.1.4. Viable Tumor Samples
6.1.1.5. Tumor Tissue Microarrays
6.2. Asia Pacific Life Science Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Drug Discovery and Development
6.2.1.2. Basic Research
6.2.1.3. Toxicity Screening
6.2.1.4. Biopharmaceutical Production
6.2.1.5. Drug Screening
6.2.1.6. Tissue Engineering
6.2.1.7. Forensic Testing
6.3. Asia Pacific Life Science Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Biopharmaceutical Companies
6.3.1.2. Contract Research Organizations (CROs)
6.3.1.3. Academic & Research Institutes
6.3.1.4. Forensic Science Laboratories
6.3.1.5. Food & Beverage Companies
6.3.1.6. Diagnostic Centers
6.3.1.7. Others
6.4. Asia Pacific Life Science Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Life Science Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Life Science Market End User, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Life Science Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Life Science Market End User, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Life Science Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Life Science Market End User, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Life Science Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Life Science Market End User, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Life Science Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Life Science Market End User, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Life Science Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Life Science Market End User, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Life Science Market Outlook, 2018 - 2031
7.1. Latin America Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Recombinant Proteins
7.1.1.1.1. Immune Checkpoint Regulators
7.1.1.1.2. Chemokines
7.1.1.1.3. Growth Factors
7.1.1.1.4. Cytokines
7.1.1.1.5. Colony Stimulating Factors
7.1.1.1.6. Hormones
7.1.1.1.7. Enzymes and Inhibitors
7.1.1.1.8. Others
7.1.1.2. Cell Lines
7.1.1.2.1. Immunotherapy Cell Lines
7.1.1.2.2. Ion Channel Cell Lines
7.1.1.2.3. GPCR Cell Lines
7.1.1.2.4. Cell Signaling Pathway Cell Lines
7.1.1.2.5. Gene Knockout Cell Lines
7.1.1.2.6. Cancer Cell Lines
7.1.1.2.7. Others
7.1.1.3. Antibodies
7.1.1.3.1. Immune Checkpoint Antibodies
7.1.1.3.2. Epitope Tag Antibodies
7.1.1.3.3. Isotype Control Antibodies
7.1.1.3.4. Primary Antibodies
7.1.1.3.5. Assay Antibodies
7.1.1.3.6. Others
7.1.1.4. Viable Tumor Samples
7.1.1.5. Tumor Tissue Microarrays
7.2. Latin America Life Science Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Drug Discovery and Development
7.2.1.2. Basic Research
7.2.1.3. Toxicity Screening
7.2.1.4. Biopharmaceutical Production
7.2.1.5. Drug Screening
7.2.1.6. Tissue Engineering
7.2.1.7. Forensic Testing
7.3. Latin America Life Science Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Biopharmaceutical Companies
7.3.1.2. Contract Research Organizations (CROs)
7.3.1.3. Academic & Research Institutes
7.3.1.4. Forensic Science Laboratories
7.3.1.5. Food & Beverage Companies
7.3.1.6. Diagnostic Centers
7.3.1.7. Others
7.4. Latin America Life Science Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Life Science Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Life Science Market End User, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Life Science Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Life Science Market End User, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Life Science Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Life Science Market End User, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Life Science Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Life Science Market End User, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Life Science Market Outlook, 2018 - 2031
8.1. Middle East & Africa Life Science Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Recombinant Proteins
8.1.1.1.1. Immune Checkpoint Regulators
8.1.1.1.2. Chemokines
8.1.1.1.3. Growth Factors
8.1.1.1.4. Cytokines
8.1.1.1.5. Colony Stimulating Factors
8.1.1.1.6. Hormones
8.1.1.1.7. Enzymes and Inhibitors
8.1.1.1.8. Others
8.1.1.2. Cell Lines
8.1.1.2.1. Immunotherapy Cell Lines
8.1.1.2.2. Ion Channel Cell Lines
8.1.1.2.3. GPCR Cell Lines
8.1.1.2.4. Cell Signaling Pathway Cell Lines
8.1.1.2.5. Gene Knockout Cell Lines
8.1.1.2.6. Cancer Cell Lines
8.1.1.2.7. Others
8.1.1.3. Antibodies
8.1.1.3.1. Immune Checkpoint Antibodies
8.1.1.3.2. Epitope Tag Antibodies
8.1.1.3.3. Isotype Control Antibodies
8.1.1.3.4. Primary Antibodies
8.1.1.3.5. Assay Antibodies
8.1.1.3.6. Others
8.1.1.4. Viable Tumor Samples
8.1.1.5. Tumor Tissue Microarrays
8.2. Middle East & Africa Life Science Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Drug Discovery and Development
8.2.1.2. Basic Research
8.2.1.3. Toxicity Screening
8.2.1.4. Biopharmaceutical Production
8.2.1.5. Drug Screening
8.2.1.6. Tissue Engineering
8.2.1.7. Forensic Testing
8.3. Middle East & Africa Life Science Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Biopharmaceutical Companies
8.3.1.2. Contract Research Organizations (CROs)
8.3.1.3. Academic & Research Institutes
8.3.1.4. Forensic Science Laboratories
8.3.1.5. Food & Beverage Companies
8.3.1.6. Diagnostic Centers
8.3.1.7. Others
8.4. Middle East & Africa Life Science Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Life Science Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Life Science Market End User, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Life Science Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Life Science Market End User, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Life Science Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Life Science Market End User, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Life Science Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Life Science Market End User, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Life Science Market by Product Type, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Life Science Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Life Science Market End User, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product Type vs End User Heatmap
9.2. Manufacturer vs End User Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Abcam Plc
9.5.1.1. Company Overview
9.5.1.2. Product Type Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. A.M.S. Biotechnology (Europe) Limited
9.5.2.1. Company Overview
9.5.2.2. Product Type Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Bio-Rad Laboratories Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Type Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. BPS Bioscience Inc.
9.5.4.1. Company Overview
9.5.4.2. Product Type Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Crown Bioscience Inc.
9.5.5.1. Company Overview
9.5.5.2. Product Type Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Genscript Biotech Corporation
9.5.6.1. Company Overview
9.5.6.2. Product Type Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Merck Millipore Limited
9.5.7.1. Company Overview
9.5.7.2. Product Type Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. PerkinElmer Inc.
9.5.8.1. Company Overview
9.5.8.2. Product Type Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Sigma Aldrich Corp.
9.5.9.1. Company Overview
9.5.9.2. Product Type Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Thermo Fisher Scientific Inc.
9.5.10.1. Company Overview
9.5.10.2. Product Type Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations